Understanding the Role of Long-Acting Injectable-Buprenorphine (LAI-B) in Community Pharmacy
Description
As part of NCAP’s REMS certification initiative for LAI-B, we invite you to join us for an educational webinar on integrating LAI-B services into the community pharmacy setting. This session will cover the Brixadi® REMS certification process, product procurement, administration techniques, and ways NCAP will support your pharmacy in expanding access to OUD treatment in your community.
Speakers
June 16th at 12:00PM
June 18th at 6:30PM
Cheryl Viracola
Director of Practice Advancement
NCAP
Mina Wolfe
Grants Coordinator
NCAP
Learning Objectives:
Describe the impact of opioid use disorder (OUD) on individuals and communities and recognize the role community pharmacies can play in expanding access to treatment.
Recognize the role of long-acting injectable buprenorphine (LAI-B) in the management of OUD.
Emphasize key administration techniques and patient counseling points for Brixadi®
Describe the requirements and processes for obtaining Brixadi® REMS certification.
Members & Non-Members: FREE
June 16th at 12:00PM and June 18th at 6:30PM
Accredited for Pharmacists and Technicians: 1.0 Hour of NC-CE
Announcements
NCAP is recruiting North Carolina pharmacies to participate in a statewide REMS certification initiative for long-acting injectable buprenorphine (LAI-B) from May–September 2026.
With pharmacists now authorized to administer LAIs, pharmacies can help expand access to treatment for Opioid Use Disorder and support recovery in their communities.
Interested in participating? Click here to complete the interest form to learn more.
